Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection.

Winkler, Emma S; Gilchuk, Pavlo; Yu, Jinsheng; Bailey, Adam L; Chen, Rita E; Zost, Seth J; Jang, Hyesun; Huang, Ying; Allen, James D; Case, James Brett; Sutton, Rachel E; Carnahan, Robert H; Darling, Tamarand L; Boon, Adrianus C M; Mack, Matthias; Head, Richard D; Ross, Ted M; Crowe, James E; Diamond, Michael S

Winkler, Emma S; Gilchuk, Pavlo; Yu, Jinsheng; Bailey, Adam L; Chen, Rita E; Zost, Seth J; Jang, Hyesun; Huang, Ying; Allen, James D; Case, James Brett; Sutton, Rachel E; Carnahan, Robert H; Darling, Tamarand L; Boon, Adrianus C M; Mack, Matthias; Head, Richard D; Ross, Ted M; Crowe, James E; Diamond, Michael S.

bioRxiv ; 2020 Dec 28.

Article en En | MEDLINE | ID: mdl-33398272

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781307
https://dx.doi.org/10.1101/2020.12.28.424554

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2020 Tipo del documento: Article